Gene · 8019
Papers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,104
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. | Pharmaceutics | 2023 | 38004560 | PubTator, text mining | PubMed |
| Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting. | Int J Mol Sci | 2023 | 38003594 | PubTator, text mining | PubMed |
| PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. | Int J Mol Sci | 2023 | 38003535 | PubTator, text mining | PubMed |
| Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. | Cancers (Basel) | 2023 | 38001750 | PubTator, text mining | PubMed |
| New cytotoxic dammarane type saponins from Ziziphus spina-christi. | Sci Rep | 2023 | 37996449 | PubTator, text mining | PubMed |
| mRNA display reveals a class of high-affinity bromodomain-binding motifs that are not found in the human proteome. | J Biol Chem | 2023 | 37992806 | PubTator, text mining | PubMed |
| Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional Regulation. | J Am Chem Soc | 2023 | 37992275 | PubTator, text mining | PubMed |
| Pan-cancer landscape of epigenetic factor expression predicts tumor outcome. | Commun Biol | 2023 | 37973839 | PubTator, text mining | PubMed |
| Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy. | Acta Pharm Sin B | 2023 | 37969742 | PubTator, text mining | PubMed |
| The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling. | Breast Cancer Res | 2023 | 37968653 | PubTator, text mining | PubMed |
| Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe. | J Med Chem | 2023 | 37967462 | PubTator, text mining | PubMed |
| Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases. | Signal Transduct Target Ther | 2023 | 37953273 | PubTator, text mining | PubMed |
| Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer. | Adv Sci (Weinh) | 2023 | 37949681 | PubTator, text mining | PubMed |
| Erratum for the Research Article: "Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis". | Sci Adv | 2023 | 37948531 | PubTator, text mining | PubMed |
| Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. | Signal Transduct Target Ther | 2023 | 37926722 | PubTator, text mining | PubMed |
| Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP. | J Biol Chem | 2023 | 37926283 | PubTator, text mining | PubMed |
| Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead. | RSC Chem Biol | 2023 | 37920397 | PubTator, text mining | PubMed |
| Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential. | Front Pharmacol | 2023 | 37920209 | PubTator, text mining | PubMed |
| Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma. | Front Oncol | 2023 | 37920164 | PubTator, text mining | PubMed |
| Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs. | J Med Chem | 2023 | 37902300 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8019/papers?page=8